Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Combining MRD assays with functional imaging in multiple myeloma

Elena Zamagni • 28 Sep 2023
IMS 2023
Multiple Myeloma

Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, briefly discusses the value of combining measurable residual disease (MRD) assays with functional imaging in patients with multiple myeloma to analyze outcomes after therapy. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Elena Zamagni

Evolution of risk stratification in SMM & MGUS: CTCs & imaging techniques
Bruno Paiva et al. • 25 Mar 2024
1:21
The impact of MRD standardized assessment by FDG-PET/CT in patients enrolled in the FORTE trial
Elena Zamagni • 28 Sep 2023
2:29
The role of various imaging techniques in multiple myeloma & the importance of optimizing these
Elena Zamagni • 28 Sep 2023
Novel therapeutic strategies in multiple myeloma
Carlos Fernández De Larrea et al. • 15 Apr 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals